Patient-Reported Outcomes of Adverse Events After Perioperative Chemotherapy for Breast Cancer: A Prospective Observational Study

This study evaluated patient-reported outcomes (PROs) of adverse events (AEs) in 116 breast cancer patients undergoing perioperative chemotherapy. Using a structured questionnaire, the study found that while gastrointestinal symptoms decreased 6 months post-chemotherapy, other AEs like peripheral sensory neuropathy, insomnia, and nail changes persisted. The anthracycline- and taxane-based regimen (A + T) was associated with higher rates of oral mucositis, neuropathy, and nail loss compared to the docetaxel/cyclophosphamide regimen (TC). The findings emphasize the importance of PROs in capturing persistent symptoms often underestimated in clinical practice and suggest that incorporating PRO-based questionnaires into follow-up care could enhance supportive management.